The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Urological Cancer Therapeutics Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
The global Urological Cancer Therapeutics Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Urological Cancer Therapeutics Drugs in various end use industries. The expanding demands from the Hospital, Medical Research Laboratory and Others,, are propelling Urological Cancer Therapeutics Drugs market. Xofigo (radium Ra 223 dichloride), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Jevtana (cabazitaxel) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Urological Cancer Therapeutics Drugs market, driven by demand from China, the second largest economy with some signs of stabilising, the Urological Cancer Therapeutics Drugs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Urological Cancer Therapeutics Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Urological Cancer Therapeutics Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Urological Cancer Therapeutics Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Urological Cancer Therapeutics Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Urological Cancer Therapeutics Drugs covered in this report include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc.
The global Urological Cancer Therapeutics Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Global Urological Cancer Therapeutics Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Urological Cancer Therapeutics Drugs market, Segment by Type:
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs market, by Application
Hospital
Medical Research Laboratory
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Urological Cancer Therapeutics Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
The global Urological Cancer Therapeutics Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Urological Cancer Therapeutics Drugs in various end use industries. The expanding demands from the Hospital, Medical Research Laboratory and Others,, are propelling Urological Cancer Therapeutics Drugs market. Xofigo (radium Ra 223 dichloride), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Jevtana (cabazitaxel) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Urological Cancer Therapeutics Drugs market, driven by demand from China, the second largest economy with some signs of stabilising, the Urological Cancer Therapeutics Drugs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Urological Cancer Therapeutics Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Urological Cancer Therapeutics Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Urological Cancer Therapeutics Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Urological Cancer Therapeutics Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Urological Cancer Therapeutics Drugs covered in this report include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc.
The global Urological Cancer Therapeutics Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Global Urological Cancer Therapeutics Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Urological Cancer Therapeutics Drugs market, Segment by Type:
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs market, by Application
Hospital
Medical Research Laboratory
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Urological Cancer Therapeutics Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Urological Cancer Therapeutics Drugs
1.1 Urological Cancer Therapeutics Drugs Market Overview
1.1.1 Urological Cancer Therapeutics Drugs Product Scope
1.1.2 Urological Cancer Therapeutics Drugs Market Status and Outlook
1.2 Global Urological Cancer Therapeutics Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Urological Cancer Therapeutics Drugs Market Size by Region (2018-2029)
1.4 Global Urological Cancer Therapeutics Drugs Historic Market Size by Region (2018-2023)
1.5 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Urological Cancer Therapeutics Drugs Market Size (2018-2029)
1.6.1 North America Urological Cancer Therapeutics Drugs Market Size (2018-2029)
1.6.2 Europe Urological Cancer Therapeutics Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size (2018-2029)
1.6.4 Latin America Urological Cancer Therapeutics Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size (2018-2029)
2 Urological Cancer Therapeutics Drugs Market by Type
2.1 Introduction
2.1.1 Xofigo (radium Ra 223 dichloride)
2.1.2 Jevtana (cabazitaxel)
2.1.3 Inlyta (axitinib)
2.1.4 Votrient (pazopanib hydrochloride)
2.1.5 Sutent (sunitinib malate)
2.1.6 Zytiga (abiraterone acetate)
2.1.7 Xtandi (enzalutamide)
2.1.8 Opdivo (nivolumab)
2.1.9 Provenge (sipuleucel-T)
2.2 Global Urological Cancer Therapeutics Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)
3 Urological Cancer Therapeutics Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Medical Research Laboratory
3.1.3 Others
3.2 Global Urological Cancer Therapeutics Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)
4 Urological Cancer Therapeutics Drugs Competition Analysis by Players
4.1 Global Urological Cancer Therapeutics Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2022)
4.3 Date of Key Players Enter into Urological Cancer Therapeutics Drugs Market
4.4 Global Top Players Urological Cancer Therapeutics Drugs Headquarters and Area Served
4.5 Key Players Urological Cancer Therapeutics Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Urological Cancer Therapeutics Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.1.4 Novartis Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.2.4 Pfizer Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 AstraZeneca Recent Developments
5.4 AstraZeneca
5.4.1 AstraZeneca Profile
5.4.2 AstraZeneca Main Business
5.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 AstraZeneca Recent Developments
5.5 Astellas
5.5.1 Astellas Profile
5.5.2 Astellas Main Business
5.5.3 Astellas Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.5.4 Astellas Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Astellas Recent Developments
5.6 Bristol-Myers Squibb
5.6.1 Bristol-Myers Squibb Profile
5.6.2 Bristol-Myers Squibb Main Business
5.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Bristol-Myers Squibb Recent Developments
5.7 Abbott Laboratories
5.7.1 Abbott Laboratories Profile
5.7.2 Abbott Laboratories Main Business
5.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Abbott Laboratories Recent Developments
5.8 Celgene Corporation
5.8.1 Celgene Corporation Profile
5.8.2 Celgene Corporation Main Business
5.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Celgene Corporation Recent Developments
5.9 Dendreon Corporation
5.9.1 Dendreon Corporation Profile
5.9.2 Dendreon Corporation Main Business
5.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Dendreon Corporation Recent Developments
5.10 Ferring Pharmaceuticals
5.10.1 Ferring Pharmaceuticals Profile
5.10.2 Ferring Pharmaceuticals Main Business
5.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Ferring Pharmaceuticals Recent Developments
5.11 GlaxoSmithKline plc
5.11.1 GlaxoSmithKline plc Profile
5.11.2 GlaxoSmithKline plc Main Business
5.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 GlaxoSmithKline plc Recent Developments
5.12 Indevus Pharmaceuticals Inc
5.12.1 Indevus Pharmaceuticals Inc Profile
5.12.2 Indevus Pharmaceuticals Inc Main Business
5.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Indevus Pharmaceuticals Inc Recent Developments
5.13 Ipsen
5.13.1 Ipsen Profile
5.13.2 Ipsen Main Business
5.13.3 Ipsen Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.13.4 Ipsen Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Ipsen Recent Developments
5.14 Roche Healthcare
5.14.1 Roche Healthcare Profile
5.14.2 Roche Healthcare Main Business
5.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Roche Healthcare Recent Developments
5.15 Sanofi S.A.
5.15.1 Sanofi S.A. Profile
5.15.2 Sanofi S.A. Main Business
5.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Products, Services and Solutions
5.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Sanofi S.A. Recent Developments
6 North America
6.1 North America Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Urological Cancer Therapeutics Drugs Market Dynamics
11.1 Urological Cancer Therapeutics Drugs Industry Trends
11.2 Urological Cancer Therapeutics Drugs Market Drivers
11.3 Urological Cancer Therapeutics Drugs Market Challenges
11.4 Urological Cancer Therapeutics Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
